Scipher and Savant Bio Partner to Build the Most Comprehensive Clinico-Genomic Dataset in Rheumatoid Arthritis
The collaboration centers on transforming real-world data from the electronic health records (EHRs) of patients tested with Scipher's clinically validated molecular signature test that predicts non-response to TNF inhibitor therapies, PrismRA ®. These data will be converted into structured, analysis-ready formats. By integrating deep genomic insights with comprehensive clinical context, the partnership aims to generate actionable real-world evidence to accelerate drug development in RA and related autoimmune conditions.
'Enormous potential is locked inside real-world clinical data, but much of it lives in an unstructured form,' said Brian Moriarty, Co-Founder of Savant Bio. 'By linking Scipher's validated genomic insights with structured patient journeys, we are creating the foundation for the next generation of real-world evidence to enable faster studies, richer evidence, and more targeted therapies in RA.'
Savant's platform uses large language models (LLMs), paired with domain-specific quality controls, to extract structured variables from free-text clinical documentation, such as physician notes and pathology reports. Key enriched dimensions include biologic sequencing, disease activity scores (e.g., CDAI, DAS28), steroid exposure, radiographic findings, and treatment durability. Each output undergoes rigorous review to ensure accuracy and consistency and can be linked to claims, labs, and prescribing data for longitudinal analysis.
'As the leader in autoimmune transcriptomic data, we've long believed that combining molecular precision with real-world outcomes is key to advancing drug development in autoimmune disease,' said Reg Seeto, CEO of Scipher Medicine. 'By integrating structured clinical data through Savant's platform, we aim to enhance the utility of the growing Scipher dataset for applications ranging from trial design to market access — and ultimately support more personalized, evidence-driven treatment strategies in autoimmune diseases.'
Initial structuring is underway on a cohort of more than 6,000 PrismRA-tested patients, creating one of the most comprehensive genomically defined RA cohorts with structured EHR data. Additional expansion is planned. The dataset will support critical use cases, including:
Validating real-world predictors of treatment response
Mapping treatment sequencing and disease control
Building precision cohorts for post-TNFi trials
Supporting post-market studies and label expansion
The enriched dataset will be made available through collaborative research initiatives, co-publications, and structured licensing partnerships. Interested organizations are encouraged to engage early to help shape use cases and gain preliminary access to insights.
About Scipher Medicine Scipher Medicine is redefining drug development in autoimmune diseases through its precision diagnostics platform, real-world data, and network biology. The company's Prism ® platform uses genomic signatures to guide therapeutic selection and generate insights into treatment response. Scipher has built the largest genomic biobank in RA, which is coupled with access to EHR data from a network of over 3 million rheumatology patients. Learn more at www.sciphermedicine.com.
About Savant Bio Savant is transforming how healthcare and life sciences organizations unlock the value trapped in unstructured medical data. Its data abstraction platform combines advanced large language models with domain-specific quality controls to convert free-text clinical records into structured, analysis-ready data — efficiently, accurately, and at scale. Backed by Roivant, Savant partners with leading institutions across healthcare, life sciences, and research to deliver sharper insights and better outcomes. Learn more at www.savantbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Amazon-Backed (AMZN) Anthropic Just Announced a Big Upgrade
Amazon-backed (AMZN) Anthropic is making a big upgrade to its Claude Sonnet 4 AI model by increasing the context window for enterprise API customers to one million tokens. For context, that is enough to handle about 750,000 words and 75,000 lines of code. This is a major jump from the previous 200,000 token limit and more than double OpenAI's GPT-5, which offers 400,000 tokens. The new long-context feature will also be available through Anthropic's cloud partners, including Amazon's Bedrock and Google (GOOGL) Cloud's Vertex AI. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. This comes as OpenAI's new GPT-5 model offers lower pricing and high coding performance. Nevertheless, Anthropic's product lead, Brad Abrams, says that he is pleased with the firm's API growth and expects the longer context to bring 'a lot of benefit' to coding platforms. Interestingly, unlike OpenAI, which earns most of its revenue from ChatGPT subscriptions, Anthropic focuses on selling AI through APIs, which makes developer-focused platforms critical to its business. The company also recently updated its largest model, Claude Opus 4.1, to improve its coding capabilities. It is worth noting that having a larger context window can make AI far better at tasks like software engineering, where seeing the entire project leads to more accurate results. Abrams said that it also improves Claude's ability to work on 'agentic' coding tasks, which are complex problems that require the AI to keep track of its steps over minutes or hours. In addition, for API users sending prompts over 200,000 tokens, costs will rise to $6 per million input tokens and $22.50 per million output tokens, up from $3 and $15, respectively. What Is the Price Target for AMZN Stock? Turning to Wall Street, analysts have a Strong Buy consensus rating on Amazon stock based on 43 Buys and one Hold assigned in the past three months. Furthermore, the average AMZN stock price target of $264.40 per share implies 19.1% upside potential from current levels.
Yahoo
2 hours ago
- Yahoo
Why Roivant Sciences Stock Bounced Back on Tuesday
Key Points A day after it published its latest set of quarterly earnings, an analyst bumped his price target higher. He also maintained his equivalent of a buy recommendation. 10 stocks we like better than Roivant Sciences › Monday's hangover turned into Tuesday's party for healthcare stock Roivant Sciences (NASDAQ: ROIV). On the back of a modest but meaningful analyst price target hike, investors bid the stock up by nearly 4% following a post-earnings slide the day before. With the Tuesday rise, Roivant handily beat the benchmark S&P 500 index, which bumped 1.1% higher. Boosting the biotech Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his recommendation of outperform (read: buy) on the company's stock. According to reports, Risinger's adjustment is based on a change in his forecast for the biotech company's share count. The analyst based this on management's statements about its share repurchase program, which is expected to shave the tally for shares outstanding. As for Roivant's operations, the pundit waxed bullish on the eventual outcome of the company's phase 3 clinical trial of brepocitinib in the treatment of dermatomyositis, a rare inflammatory disease that can affect the muscles and the skin. He's anticipating a readout of the trial to be published in the second half of this year. A first quarter to forget Risinger's continued bullishness on Roivant was a morale-booster for the market, which had traded out of the company's shares after Monday's fiscal first quarter of 2026 earnings release. The company reported significantly lower revenue compared to the same period of 2025, and it flipped to a net loss on the bottom line. Should you buy stock in Roivant Sciences right now? Before you buy stock in Roivant Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roivant Sciences wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy. Why Roivant Sciences Stock Bounced Back on Tuesday was originally published by The Motley Fool Sign in to access your portfolio
Business Wire
5 hours ago
- Business Wire
Industry Leader in Lyophilization, Dr. Serguei Tchessalov, Partners with BioTechnique ® to Enhance Customer Capabilities
YORK, Pa.--(BUSINESS WIRE)--BioTechnique ® LLC ('BioTechnique' or the 'Company') proudly welcomes Dr. Serguei Tchessalov, a globally recognized subject matter expert in lyophilization, whose decades of experience in formulation development, process design, and scale-up bring invaluable insight to clients navigating complex biologic and vaccine manufacturing. With over 40 years of experience spanning both Russia and the United States, Dr. Tchessalov brings deep expertise in the formulation and freeze-drying of bacterial, viral, and mRNA-based vaccines, proteins, and other complex biologics. He holds a Ph.D. in Biotechnology Engineering from the Institute of Applied Biochemistry in Moscow, where his research focused on novel formulation and process control methods for lyophilization. After completing postdoctoral training with Professor Michael Pikal at the University of Connecticut, he went on to hold roles at Immunex, Wyeth, and Pfizer, contributing to industry-leading development efforts. Dr. Tchessalov is the founder of SN Lyophilization, a consulting firm dedicated to freeze-drying and parenteral drug product processing. With over 30 scientific publications to his name, his current work focuses on lyophilization scale-up and transfer, as well as processing operations including filtration, filling, freezing, and thawing. His partnership with BioTechnique strengthens the company's ability to support clients with practical, science-driven solutions across the entire drug product lifecycle. BioTechnique ® 's Lyophilization Capabilities At BioTechnique ®, lyophilization is a core competency backed by robust infrastructure and scientific expertise. Our state-of-the-art, aseptic manufacturing facility is equipped to support both clinical and commercial-scale freeze-drying of biologics, including monoclonal antibodies, peptides, vaccines, and other sensitive drug products. We offer flexible lyophilizer configurations, precise cycle development, and seamless tech transfer—all executed under strict cGMP conditions. Whether clients require formulation support, cycle optimization, troubleshooting, or full-process development, BioTechnique provides tailored solutions that prioritize product stability, yield, and regulatory compliance. With Dr. Tchessalov's guidance, our clients gain not only access to advanced modeling tools and industry best practices, but also the strategic insight needed to successfully navigate the complexities of lyophilization from early development through commercialization. For more information on BioTechnique's capabilities, visit
